What is the 52 Week High and Low of Aurobindo Pharma Share Price?

The 52 week high and low prices of Aurobindo Pharma share price is 1550 & 1016.1. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Aurobindo Pharma Share price

Q: How to buy Aurobindo Pharma Share at Choice?

To buy Aurobindo Pharma stocks , log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Aurobindo Pharma, choose your preferred order type, and place the trade.

AUROPHARMA

Healthcare Large Cap

1449

2.80 (-0.19%)

NSE

BSE

Last updated on 9 Jun, 2026 | 15:53 IST

BuySell

Today's High

1469.00

Today's Low

1438.00

52 Week Low

1016.10

52 Week High

1550.00

Aurobindo Pharma Chart

ChartIQ

TradingView

Aurobindo Pharma Share Key Metrics

Volume

12.64 L

Market Cap

84158.16 CR

LTQ@LTP

5@1449.00

ATP

1454.19

Var Margin

14.43 %

Circuit Range

1306.7-1596.9

Delivery %

38.05 %

Value

183.80 CR

ASM/GSM

No

Market Lot

1

Summary

Aurobindo Pharma share price is ₹1449 as of 9 Jun, 2026. The stock Aurobindo Pharma intraday movement has stayed between ₹1438.00 and ₹1469.00, while on a 52-week basis,Aurobindo Pharma price 52 week high is ₹1550.00 & its 52 week low is ₹1016.10.

In terms of trading activity, Aurobindo Pharma has recorded a volume of 1263926 shares, The Aurobindo Pharma has a market cap of ₹580801623 CR. The stock’s Average Traded Price (ATP) stands at ₹1454.19, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 5 @ ₹1449.00.

Aurobindo Pharma operates within a circuit range of ₹1306.70 – ₹1596.90, with a Value of ₹183.80 CR. The Delivery Percentage for the day is 38.05%. Additionally, Aurobindo Pharma currently falls under the No framework, and trades with a market lot size of 1.

Aurobindo Pharma Fundamentals

P/E Ratio

23.84

P/B Ratio

2.2

Div. Yield

0.28

Sector P/E

67.41

Sector P/B

2.96

Sec. Div. Yield

0.54

Aurobindo Pharma Resistance and Support

Pivot 1458.73

Resistance

First Resistance

1471.56

Second Resistance

1491.33

Third Resistance

1504.16

Support

First Support

1438.96

Second Support

1426.13

Third Support

1406.36

Aurobindo Pharma Futures & Options

Aurobindo Pharma Ltd Share Price

1449

-2.8 (-0.19%)

Aurobindo Pharma Option Chain

View Price, OI, Greeks & More...

View All

30JUN26

1449.00

-10.20 (0.70%)

28JUL26

1459.30

-10.40 (0.71%)

25AUG26

1470.00

-4.00 (0.27%)

AUROPHARMA|30JUN26 CE 1440.00

41.55 -4.9 (-10.55%)

AUROPHARMA|30JUN26 PE 1460.00

40 3.55 (9.74%)

Aurobindo Pharma Shareholding Pattern

2016-17
2018-19
2019-20
2020-21
2021-22
2022-23
2023-24
2024-25
2025-26
2026-27

Total Promoters

Segment

Percent

Total Promoters

51.82%

Mutual Fund

17.79%

Insurance

5%

Foreign Institutional Investors

15.24%

Domestic Institutional Investors

3.08%

Retail

7.08%

Others

-0.01%

Total Promoters

MAR '26

51.82%

Aurobindo Pharma Corporate Actions

Date	Agenda
2026-05-21	Audited Results
2026-04-06	Buy Back of Shares
2026-02-09	Quarterly Results
2025-11-05	Quarterly Results
2025-08-04	Quarterly Results & Interim Dividend
2025-05-26	Audited Results
2025-02-06	Quarterly Results

Aurobindo Pharma News

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Aurobindo Pharma received final US FDA approval to manufacture and market Tofacitinib Tablets, 5 mg and 10 mg. This allows immediate launch of the product in the US market, which has an estimated market size of US$494 million.

Jun 04 2026 18:16:02

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Aurobindo Pharma inaugurated TheraNym, a large-scale biologics contract manufacturing facility in Borapatla, Hyderabad. This marks the company's strategic entry into the high-growth biologics CMO segment, with global pharma giant MSD as an anchor customer.

Jun 03 2026 17:38:00

Aurobindo Pharma Ltd - 524804 - Classification Of Unit-I Of Eugia Pharma Specialities Limited, Shameerpet (Our Wholly Owned Subsidiary) As OAI

Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities, has received an "Official Action Indicated" (OAI) classification from the US FDA for its Unit-I manufacturing facility. This classification follows an inspection that concluded with 4 observations, indicating that regulatory or administrative actions are recommended by the FDA.

May 24 2026 17:35:06

Aurobindo Pharma Ltd - 524804 - Appointment Of Secretarial Auditor

Aurobindo Pharma announced a change in its Secretarial Auditors. M/s. MRR & Associates resigned due to health issues, and M/s. RPR & Associates has been appointed for a five-year term, subject to shareholder approval.

May 21 2026 21:02:34

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Cessation

Aurobindo Pharma announced the resignation of its Secretarial Auditor, MRR & Associates, effective May 22, 2026, citing health issues of the sole proprietor. The board has approved the appointment of RPR & Associates as the new Secretarial Auditor for five years, commencing from FY 2026-27, subject to shareholder approval.

May 21 2026 20:53:45

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Aurobindo Pharma announced its Q4 FY26 consolidated financial results, with revenue growing 5.6% YoY to Rs.8,853 Cr. Net profit increased by 2.0% to Rs.921 Cr, while EBITDA margin before R&D stood at 24.5% amid mixed segment performance.

May 21 2026 20:45:10

Aurobindo Pharma Ltd - 524804 - Board Meeting Outcome for Outcome Of Board Meeting

Aurobindo Pharma's board approved Q4 & FY26 consolidated financial results, reporting ₹87,515.0 mn revenue and ₹9,208.4 mn net profit for Q4. M/s. MRR & Associates resigned as Secretarial Auditor, and M/s. RPR & Associates was appointed for five years from FY27.

May 21 2026 19:43:02

Aurobindo Pharma Ltd - 524804 - Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

The Hon'ble High Court of Telangana dismissed the writ petition filed by Aurobindo Pharma's promoter group, challenging a SEBI order related to alleged insider trading. This upholds SEBI's directive for promoters to deposit Rs.6.53 crores plus interest into the Investor Protection and Education Fund.

May 16 2026 21:40:38

Aurobindo Pharma Ltd - 524804 - Curateq Biologics Receives CDSCO Marketing Authorisation (Form CT 23) For Bevqolva® (Bevacizumab Biosimilar)

Aurobindo Pharma's wholly owned subsidiary, CuraTeQ Biologics, has received CDSCO Marketing Authorisation for Bevqolva®, a bevacizumab biosimilar. This approval permits manufacturing at its Hyderabad facility and marketing for metastatic carcinoma of the colon or rectum, marking a significant product launch.

May 16 2026 10:03:52

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Closure of Buy Back

Aurobindo Pharma completed its Rs. 800 crore buyback program, extinguishing 54.23 lakh equity shares. This action reduces the company's total equity share capital from 58.08 crore to 57.53 crore shares.

May 15 2026 19:03:28

Name	Position
Mangalam Ramasubramanian Kumar	Chairman
K Nityananda Reddy	Vice Chairman & Managing Director

Aurobindo Pharma Similar Stocks

Dr. Reddy's Laboratories Ltd.

1268.50

-7.10 (0.56%)

Lupin Ltd.

2264.20

9.70 (0.43%)

Mankind Pharma Ltd.

2391.00

33.60 (1.43%)

Max Healthcare Institute Ltd.

1003.10

-4.35 (0.43%)

Lenskart Solutions Ltd.

503.40

-1.25 (0.25%)

Laurus Labs Ltd.

1424.40

19.70 (1.40%)

Fortis Healthcare Ltd.

989.75

0.65 (0.07%)

Biocon Ltd.

416.35

7.10 (1.73%)

Alkem Laboratories Ltd.

5355.50

-1.00 (0.02%)

Aurobindo Pharma FAQs

The Buying Price of Aurobindo Pharma share is 1449 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Aurobindo Pharma stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Aurobindo Pharma, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Aurobindo Pharma shares is 23.84. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Aurobindo Pharma shares is 2.2. Useful to assess the stock's value relative to its book value.

To assess Aurobindo Pharma’s valuation compare Sector P/E, P/B which are 67.41 & 2.96 with sector averages, along with growth rates and financial metrics.

The Market Cap of Aurobindo Pharma is 84158.16 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Aurobindo Pharma share price is 1550.00 & 1016.10. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Aurobindo Pharma belongs to the Healthcare sector.